ipamorelin vs sermorelin: Frequently asked questions

Sermorelin is better suited. Its front-loaded pulse reaches peak plasma GH within 30–45 minutes and declines rapidly, creating a defined exposure window. This is ideal for experiments measuring immediate downstream signalling (STAT5 phosphorylation, IGF-1 transcription) where you want maximal receptor occupancy within a narrow timeframe. Ipamorelin's gradual rise and sustained plateau make it harder to pinpoint acute effects.

Ipamorelin's slower desensitisation kinetics support longer continuous protocols. GHRH receptors downregulate faster than GHS-R1a receptors under chronic agonist exposure. Sermorelin typically shows diminished response by day 5–7, while Ipamorelin maintains consistent GH output through day 10–12. If your hypothesis requires stable GH elevation over weeks, Ipamorelin is the mechanistically appropriate choice.

Choose Ipamorelin. GHS-R1a activation does not trigger ACTH release, so cortisol remains at baseline even at doses exceeding standard protocols by 5-fold. This matters in models involving chronic stress, metabolic syndrome, or neurodegenerative conditions where HPA axis variability introduces noise. Sermorelin's GHRH pathway can indirectly influence cortisol through hypothalamic feedback, particularly at high doses or in subjects with pre-existing HPA dysregulation.

Ipamorelin is non-negotiable. Any protocol measuring insulin sensitivity, lipolysis, or anabolic signaling cannot tolerate cortisol interference. Cortisol directly antagonizes insulin signaling, promotes muscle protein breakdown, and shifts substrate utilization toward gluconeogenesis. Ipamorelin's selectivity for GHS-R1a means zero cortisol cross-reactivity at research doses. Sermorelin has low but measurable cortisol impact in 5–10% of administrations, particularly when dosed above 300 mcg or in subjects with elevated baseline stress hormones.

Sermorelin outperforms when dosed correctly. If your protocol measures peak GH concentration as the primary outcome and you can control timing to align with natural nocturnal GH surges, sermorelin produces 30–50% higher peak amplitude than ipamorelin at equivalent molar doses. The trade-off is variance. Sermorelin's response depends on the subject's baseline GH secretion capacity, whereas ipamorelin's response is more uniform across individuals. If you need power over precision, sermorelin is the answer.

Both work, but the combination logic differs. CJC-1295 Ipamorelin 5MG 5MG is a common research stack because CJC-1295 (a GHRH analog with extended half-life) provides sustained baseline GH elevation, while ipamorelin adds discrete pulses on top of that elevated baseline. The result is higher average GH concentration across 24 hours. Stacking sermorelin with CJC-1295 is redundant because both are GHRH analogs acting on the same receptor pathway. You'd simply increase sermorelin dose rather than add CJC.

Choose ipamorelin. Its receptor-mediated mechanism allows 2–3 administrations per day without desensitization or rhythm disruption. Standard protocols dose at morning (fasted), post-training, and pre-sleep. Sermorelin's dependence on endogenous GHRH rhythm makes multiple daily doses less effective because you're trying to amplify a pulse that may not exist mid-day. Research from the Journal of Clinical Endocrinology found that ipamorelin dosed three times daily maintained consistent GH elevation across all time points, whereas sermorelin dosed identically showed 40% lower response at the mid-day administration.